{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:43:45Z","timestamp":1692906225124},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00108-023-01568-0","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T14:02:15Z","timestamp":1691157735000},"page":"842-847","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leichtkettenamyloidose","Light chain amyloidosis"],"prefix":"10.1007","volume":"64","author":[{"given":"Ute","family":"Hegenbart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"aus dem Siepen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri\u00a0A, Gertz\u00a0MA (2004) Serum cardiac troponins and N\u2011terminal pro-brain natriuretic peptide: a\u00a0staging system for primary systemic amyloidosis. J\u00a0Clin Oncol 22:3751\u20133757","journal-title":"J Clin Oncol"},{"key":"1568_CR2","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","volume":"138","author":"CV Edwards","year":"2021","unstructured":"Edwards\u00a0CV, Rao\u00a0N (2021) Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood 138:2632\u20132641","journal-title":"Blood"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ajh.26569","volume":"97","author":"MA Gertz","year":"2022","unstructured":"Gertz\u00a0MA (2022) Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol 97:818\u2013829","journal-title":"Am J Hematol"},{"key":"1568_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019406","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, Cohen AD (2023) Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. https:\/\/doi.org\/10.1182\/blood.2022019406","journal-title":"Blood"},{"key":"1568_CR5","volume-title":"National Clinical Amyloidosis Registry. ISA Meeting, Heidelberg, Germany","author":"U Hegenbart","year":"2022","unstructured":"Hegenbart\u00a0U, Bari\u00a0A (2022) The distribution of amyloidosis diseases in Germany. In: National Clinical Amyloidosis Registry. ISA Meeting, Heidelberg, Germany"},{"key":"1568_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis\u00a0E, Palladini\u00a0G (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N\u00a0Engl J Med 385:46\u201358","journal-title":"N Engl J Med"},{"key":"1568_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","volume":"37","author":"AV Kristen","year":"2018","unstructured":"Kristen\u00a0AV, Kreusser\u00a0MM (2018) Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J\u00a0Heart Lung Transplant 37:611\u2013618","journal-title":"J Heart Lung Transplant"},{"key":"1568_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar\u00a0S, Dispenzieri\u00a0A (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J\u00a0Clin Oncol 30:989\u2013995","journal-title":"J Clin Oncol"},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","volume":"41","author":"E Muchtar","year":"2023","unstructured":"Muchtar\u00a0E, Dispenzieri\u00a0A (2023) Graded cardiac response criteria for patients with systemic light chain amyloidosis. J\u00a0Clin Oncol 41:1393\u20131403","journal-title":"J Clin Oncol"},{"key":"1568_CR10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283325","author":"S Oubari","year":"2023","unstructured":"Oubari S, Hegenbart U (2023) Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.283325","journal-title":"Haematologica"},{"key":"1568_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini\u00a0G, Hegenbart\u00a0U (2014) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124:2325\u20132332","journal-title":"Blood"},{"key":"1568_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","volume":"28","author":"G Palladini","year":"2021","unstructured":"Palladini\u00a0G, Sch\u00f6nland\u00a0SO (2021) Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 28:1\u20132","journal-title":"Amyloid"},{"key":"1568_CR13","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2020008737","volume":"139","author":"G Palladini","year":"2022","unstructured":"Palladini\u00a0G, Merlini\u00a0G (2022) How I treat AL amyloidosis. Blood 139:2918\u20132930","journal-title":"Blood"},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards\u00a0DB, Cookson\u00a0LM (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N\u00a0Engl J Med 373:1106\u20131114","journal-title":"N Engl J Med"},{"key":"1568_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","volume":"29","author":"V Sanchorawala","year":"2022","unstructured":"Sanchorawala\u00a0V, Boccadoro\u00a0M (2022) Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid 29:1\u20137","journal-title":"Amyloid"},{"key":"1568_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron\u00a0A, Zheng\u00a0L (2021) Marked progress in AL amyloidosis survival: a\u00a040-year longitudinal natural history study. Blood Cancer\u00a0J 11:1\u201310","journal-title":"Blood Cancer J"},{"key":"1568_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/cncy.21523","volume":"123","author":"II Van Gameren","year":"2015","unstructured":"Van Gameren\u00a0II (2015) The role of abdominal fat tissue FNA for early detection and typing of systemic amyloidosis. Cancer Cytopathol 123:139\u2013140","journal-title":"Cancer Cytopathol"},{"issue":"121","key":"1568_CR18","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"2013","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar\u00a0AD, Schonland\u00a0SO (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013(121):3420\u20133427","journal-title":"Blood"},{"key":"1568_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar\u00a0AD, Fontana\u00a0M (2022) AL Amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: Cardiooncology state-of-the-art review. JACC Cardiooncol 4:427\u2013441","journal-title":"JACC Cardiooncol"},{"key":"1568_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","volume":"30","author":"AD Wechalekar","year":"2023","unstructured":"Wechalekar\u00a0AD, Cibeira\u00a0MT (2023) Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid 30:3\u201317","journal-title":"Amyloid"},{"key":"1568_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00108-011-2952-y","volume":"53","author":"S Sch\u00f6nland","year":"2012","unstructured":"Sch\u00f6nland\u00a0S, Blank\u00a0N, Kristen\u00a0A et\u00a0al (2012) Systemische Amyloidosen. Internist 53:51\u201364","journal-title":"Internist"},{"key":"1568_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11560-014-0957-y","volume":"10","author":"J Beimler","year":"2015","unstructured":"Beimler\u00a0J, Sch\u00f6nland\u00a0S, Blank\u00a0N et\u00a0al (2015) Aktuelle Diagnostik und Therapie der wichtigsten systemischen Amyloidosen. Nephrologe 10:303\u2013309","journal-title":"Nephrologe"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01568-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:02:55Z","timestamp":1692806575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01568-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01568-0","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"17 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Hegenbart: Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge: Janssen, Pfizer, Alnylam, Akcea, Prothena. Finanzielle Unterst\u00fctzung von Kongressteilnahmen: Janssen, Prothena, Pfizer. Advisory Boards: Pfizer, Prothena, Janssen. Finanzielles Sponsoring des Amyloidose-Registers: Janssen. F.\u00a0aus dem Siepen: Vortragshonorare von Pfizer, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Janssen. Beraterhonorare von Pfizer, Akcea Therapeutics. S.\u00a0Sch\u00f6nland: Forschungsunterst\u00fctzung von Janssen, Prothena, Neurimmune und Sanofi. Advisory Boards f\u00fcr Janssen, Telix und Prothena. Honorare von Janssen, Takeda, Pfizer und Prothena. Reisekostenunterst\u00fctzung und Unterst\u00fctzung bei Kongressteilnahmen von Janssen, Prothena, Celgene, Binding Site und Jazz.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}